% | $
Quotes you view appear here for quick access.

FRX Message Board

  • frankposting frankposting Sep 15, 2012 4:39 PM Flag

    Looking Forward

    Mar11-Mar12 EPS $3.7
    Mar12-Mar13 EPS $0.7
    Mar13-Mar14 EPS $1.5
    Mar14-Mar15 EPS $2.2
    Mar15-Mar16 EPS $1.2
    Mar16-Mar17 EPS $2.0

    If everything goes well, FRX's EPS may retake $3 level in 2019. But with changing marketing environment, "everything goes well" means high risks. Cariprazine is what FRX's future is relying on. However, the Seroquel generics has already hiitted the market, and once-daily Seroqual XL generics will hit the market in January 2016.

    Carl Ichan owned 30.66M shares. Adding an increment of 1.2M shares will reach the 12% limit. And it is hard to understand what is Ichan's real intention.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Another bad news for Cariprazine: Abilify (aripiprazole) will be genericized in April 2015. Note that Seroquel (quetiapine) already hitted the merket. Both Seroquel and Abilify are highly effective and safe. It is hard for Cariprazine to compete in such a genericized market.

99.00-0.77(-0.77%)Jun 30 4:00 PMEDT